Genetic Technologies Limited
GENE · NASDAQ
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -25.9% | 52.3% | 5,536.3% | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 50.9% | 58.1% | 95.3% | -199.5% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -149.1% | -108.3% | -106% | -5,460.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -156.8% | -113.6% | -104.9% | -5,870.9% |
| EPS Diluted | -2.73 | -3.6 | -2.32 | -2.48 |
| % Growth | 24.2% | -55.2% | 6.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |